Phase 1 × Terminated × Triple Negative Breast Neoplasms × Clear all A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase 1 Terminated
36 enrolled 7 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Phase 1 Terminated
154 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Phase 1 Terminated
18 enrolled 9 charts
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Phase 1 Terminated
16 enrolled
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
12 enrolled
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase 1 Terminated
6 enrolled
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Phase 1 Terminated
66 enrolled
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1 Terminated
41 enrolled 24 charts
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Phase 1 Terminated
31 enrolled
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Phase 1 Terminated
21 enrolled 19 charts
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Phase 1 Terminated
60 enrolled
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
Phase 1 Terminated
1 enrolled 10 charts
A Study of LY3435151 in Participants With Solid Tumors
Phase 1 Terminated
2 enrolled 8 charts
MK-8628-006
Phase 1 Terminated
13 enrolled 20 charts
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Phase 1 Terminated
60 enrolled
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
Phase 1 Terminated
28 enrolled 25 charts
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Phase 1 Terminated
21 enrolled
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
Phase 1 Terminated
1 enrolled 3 charts
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
Phase 1 Terminated
60 enrolled 44 charts
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Phase 1 Terminated
40 enrolled 26 charts
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase 1 Terminated
18 enrolled
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Phase 1 Terminated
46 enrolled
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Phase 1 Terminated
14 enrolled
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase 1 Terminated
13 enrolled
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Phase 1 Terminated
11 enrolled